Gene Therapy Trial at the Retina Foundation of the Southwest featured in The Dallas Morning News
Mason Two Crow, 22, first came to the Retina Foundation in 2003 with a diagnosis of X-linked retinoschisis, a rare genetic condition affecting the retina. Two years ago he came in for a follow-up appointment where he learned that he had the opportunity to be one of the very first to ever be enrolled in a gene therapy trial for his rare eye disease. Mason gives credit to the research scientists at the Retina Foundation for gifting him with the hope that a cure for X-linked retinoschisis may be on the horizon. Click here to read more of Mason’s incredible story on www.dallasnews.com.
Related ArticlesPediatric Lab Sees 10,000th Patient! Introducing the Vision and Neurodevelopment Laboratory The Effectiveness of Therapeutic Drugs for AMD in the Laboratory Join Drew Brees and the Retina Foundation for the Third Annual Visionary Luncheon – March 4, 2020 Early Detection is Critical for Rare Eye Diseases